Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice
about
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Micafungin.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.New investigational antifungal agents for treating invasive fungal infections.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisThe echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsMicafungin: pharmacology, experimental therapeutics and clinical applications.Echinocandin antifungals: review and update.Developments in the treatment of candidiasis: more choices and new challenges.Micafungin: a new echinocandin antifungal.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders.Eradication of invasive mucormycosis--effectiveness of the Echinocandin FK463.Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients.Toxicity of topical antifungal agents to stratified human cultivated corneal epithelial sheets.In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.New agents for the treatment of systemic fungal infections--current status.Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.
P2860
Q33530441-27D7D2E2-024C-4032-BA27-FF1EC03974AAQ33980368-B90E9E41-59CC-4E2E-ABE5-6DFC509111F0Q33981019-84EB7981-B9AA-43EC-9194-786524C59086Q33983506-21F3EAAE-9629-4EC3-AEEE-7B5DE7EDE540Q34075014-C466AD61-C5A6-465E-9809-C81385A46A05Q34108880-1D5C1C45-02CF-4E62-9AFD-983766B21657Q34881309-D513411E-6705-4103-9A12-58B620CE80A5Q34884594-3C5D7096-0DE1-44BC-9C67-C0BA08B5E6BDQ35026516-4B34D2E1-6A1B-4558-AB6B-47FEAC154D9DQ35185757-B5E438F4-D302-4CE4-9723-5456AA37BBB2Q35635928-F91B03E6-7CAB-47AF-9A03-553489C95836Q36120798-7597DFC1-3E79-49D8-AE3E-83E979C6375BQ36441524-EEAC3A89-8EFF-4E8E-B651-B40CF5BCEB63Q36623050-2D2649FC-5DF1-463F-AAA6-80599CFEC825Q36693843-50A6CD09-A6F1-46DC-AAC5-F8294446FDC1Q36828156-E8C5DAFC-39F9-48B3-A87A-830E77AB004BQ39743508-CE79837C-DAA1-45AC-853D-3384B89EF32AQ39792671-684179E1-E0DF-4339-85D4-FA5146EC8358Q40313049-A6AB3502-60B8-4795-AB06-835A74C0C917Q40559190-1F81B0A9-E572-4ABC-AF91-B1E00D611908Q42104395-72E5BF06-B29B-4583-8C0A-73503232B494Q42163324-C83E4B3C-73E4-4062-B5E2-143445803EDEQ43058460-62FEDA6E-426B-4B67-BA22-6575C5923A83Q44178484-645B9494-497D-4B05-8E54-2AAF772787BBQ44685491-3A0A0230-CD4A-40FF-A0E6-CDAD75DA58A5Q45280467-A5EACDEC-2DEE-4E4E-BB99-6EA9302D707EQ46576615-E9048698-4FD3-4E17-8175-C7696CE80116Q46707135-D9250A6E-3580-4FBA-A4CC-6F9798F64364
P2860
Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@ast
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@en
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@nl
type
label
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@ast
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@en
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@nl
prefLabel
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@ast
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@en
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@nl
P2093
P2860
P1476
Efficacy of FK463, a (1,3)-bet ...... ida albicans infection in mice
@en
P2093
P2860
P304
P356
10.1128/AAC.44.6.1728-1730.2000
P407
P577
2000-06-01T00:00:00Z